Indications for Pemigatinib

Pemigatinib (Pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. The current indication indicates that it can be used to treat patients with previously treated, unresectable locally advanced disease. It is also indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangements in adults with stage or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements detected by an FDA-approved test.

Patients may take oral pemetinib tablets once daily as directed by their physician, and in cholangiocarcinoma, take the tablets continuously for 14 days, and then stop treatment for 7 days in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity occurs. In myeloid/lymphoid neoplasms with FGFR1 rearrangements, take the tablet once daily. Continue treatment until disease progression or unacceptable toxicity occurs.

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).